Phase I study of low-dose hypomethylating agent azacitidine combined with histone deacetylase inhibitor valproic acid in patients with advanced cancers

Trial Profile

Phase I study of low-dose hypomethylating agent azacitidine combined with histone deacetylase inhibitor valproic acid in patients with advanced cancers

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs Azacitidine; Valproic acid
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 26 Jun 2009 Actual end date (1 Oct 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top